Lead Intelligent, SGMICRO, and ChipScreen List on HKEX Main Board in A+H WaveCoinLive·Jun 27 at 03:00 AM300661+6.05%00470-7.00%
The China Securities Convertible Bond Index opened down 0.15%, reporting 528.92 points. Jin 25 Convertible Bond, Newtouch Convertible Bond, Zhenhua Convertible Bond, Chipscreen Convertible Bond, and Thalys Convertible Bond had the largest declines, falling by 5.24%, 4.04%, 3.02%, 2.74%, and 2.48%, respectively. NAIPU MINING Convertible Bond 02, Novoray Convertible Bond, HAOMEI Convertible Bond, TOPSCORE FASHION Convertible Bond, and Huakang Clean Convertible Bond had the largest increases, rising by 30.00%, 8.96%, 3.27%, 2.97%, and 1.74%, respectivelyWallstreetcn·Jan 29 at 07:30 PM301235-3.68%中证转债0.00%
19:45 ET Dr. Lu Xianping, Founder, Chairman of Chipscreen Biosciences named the Chinese mainland winner of the EY Entrepreneur Of The Year™ 2025 awardsprnewswire·Dec 29, 2025 at 06:46 PM688321+0.85%
Chipscreen plans to repurchase shares for 10 million to 15 million yuanZhitong·Oct 31, 2025 at 05:01 AM688321+0.85%
Chipscreen: The net profit for the third quarter is 41.1753 million yuanZhitong·Oct 30, 2025 at 05:48 AM688321+0.85%
Chipscreen: Bio-Thera Solutions plans to reduce its holdings by no more than 3% of sharesZhitong·Sep 10, 2025 at 06:29 AM688321+0.85%
Chipscreen released its semi-annual performance, with a net profit attributable to the parent company of 29.59 million yuan, turning a profit compared to the same period last yearZhitong·Aug 25, 2025 at 03:14 AM688321+0.85%
Chipscreen: Application for the issuance of A-shares to specific targets has been acceptedZhitong·Aug 22, 2025 at 04:29 AM688321+0.85%
Chipscreen Biosciences' brain-penetrant CS231295 tablet gets FDA IND approval, advancing global clinical dev.Unusual Whales·Jul 31, 2025 at 04:59 AM688321+0.85%
05:55 ET Chipscreen Biosciences' Brain-Penetrant Aurora B Selective Inhibitor CS231295 Tablet Receives FDA IND Approval, Advancing Global Clinical Developmentprnewswire·Jul 31, 2025 at 04:57 AM688321+0.85%
Chipscreen: CS231295 clinical trial application approved by FDAZhitong·Jul 31, 2025 at 03:50 AM688321+0.85%
Chipscreen today conducted a block trade at a discount, with 1.8994 million shares traded, totaling 58.1216 million yuanZhitong·Jul 29, 2025 at 04:29 AM688321+0.85%
Chipscreen expects a profit, with an estimated net profit attributable to the parent company of approximately 30.06 million yuan in the first half of the yearZhitong·Jul 17, 2025 at 03:08 AM688321+0.85%
Chipscreen: The top-line analysis data of the Phase III clinical trial of Sidakibart for the first-line treatment of diffuse large B-cell lymphoma has been obtainedZhitong·Jul 9, 2025 at 03:03 AM688321+0.85%
Innovative drug concept stocks rise again, Chipscreen and Cosunter increase by over 10%Zhitong·Jul 6, 2025 at 08:38 PM688321+0.85%300436-8.00%
